Analysts are waiting for more data about telaprever next month and about the Merck
drug at the big liver meeting this fall, since Merck
released only partial data. Meanwhile, Merck may have one key advantage, though - a strong familiarity with the hepatitis C market thanks to its acquistion last year of Schering-Plough. “This should not be underestimated,” Sanford Bernstein analyst Tim Anderson writes in an investor note, who expects the Vertex drug to ring up $4.3 billion in sales in 2015.